Background: Studies suggest that immune checkpoint inhibitors may represent a promising strategy for boosting immune responses and improving the antitumor activity of standard therapies in patients with relapsed/refractory hematologic malignancies.
Aims: Phase 1/2 FUSION NHL 001 was designed to determine the safety and efficacy of durvalumab, an anti-programmed death ligand 1 (PD-L1) antibody, combined with standard-of-care therapies for lymphoma or chronic lymphocytic leukemia (CLL).
Methods And Results: The primary endpoints were to determine the recommended phase 2 dose of the drugs used in combination with durvalumab (durvalumab was administered at the previously recommended dose of 1500 mg every 4 weeks) and to assess safety and tolerability. Patients were enrolled into one of four arms: durvalumab monotherapy (Arm D) or durvalumab in combination with lenalidomide ± rituximab (Arm A), ibrutinib (Arm B), or rituximab ± bendamustine (Arm C). A total of 106 patients with relapsed/refractory lymphoma were enrolled. All but two patients experienced at least one treatment-emergent adverse event (TEAE); those not experiencing a TEAE were in Arm C (diffuse large B-cell lymphoma [DLBCL]) and Arm D (DLBCL during the durvalumab monotherapy treatment period). No new safety signals were identified, and TEAEs were consistent with the respective safety profiles for each study treatment. Across the study, patients with follicular lymphoma (FL; n = 23) had an overall response rate (ORR) of 59%; ORR among DLBCL patients (n = 37) was 18%. Exploratory biomarker analysis showed that response to durvalumab monotherapy or combination therapy was associated with higher interferon-γ signature scores in patients with FL (p = .02).
Conclusion: Durvalumab as monotherapy or in combination is tolerable but requires close monitoring. The high rate of TEAEs during this study may reflect on the difficulty in combining durvalumab with full doses of other agents. Durvalumab alone or in combination appeared to add limited benefit to therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875673 | PMC |
| http://dx.doi.org/10.1002/cnr2.1662 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Indirect Treatment Comparison of Lenvatinib for the First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma.
Adv Ther
December 2024
Source Health Economics, London, UK.
Introduction: This study compared the relative efficacy of first-line lenvatinib, a standard-of-care treatment for unresectable hepatocellular carcinoma (uHCC), vs licensed/license in-progress comparators. Using inverse probability of treatment weighting (IPTW) and network meta-analysis (NMA), updated evidence for lenvatinib monotherapy from LEAP-002, in addition to evidence from REFLECT, was included in the analyses.
Methods: Randomized controlled trials (RCTs) were identified via systematic review.
Comparison of treatment regimens for unresectable stage III epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer.
Chin Med J (Engl)
December 2024
Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China.
Article Synopsis
- The PACIFIC study showed that durvalumab after chemoradiotherapy did not improve survival in patients with EGFR mutations, leading researchers to investigate tyrosine kinase inhibitors (TKIs) for locally advanced inoperable patients with these mutations.
- A meta-analysis of 16 studies involving 1156 patients was conducted, comparing various treatments like CRT, CRT-Durva, TKI monotherapy, and combinations of TKI with radiotherapy or CRT, highlighting that TKI-containing treatments significantly outperformed TKI-free treatments in progression-free survival (PFS).
- The analysis found that radiotherapy combined with TKI (RT-TKI) offered the best overall survival (OS) and P
Outcomes Following Treatment for Progression in Patients Treated With Durvalumab Consolidation in LA-NSCLC.
Clin Lung Cancer
November 2024
Division of Hematology & Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Introduction: PACIFIC established consolidative durvalumab for LA-NSCLC, but only about half of patients completed a year of therapy. Data on treatment patterns and outcomes after durvalumab are limited.
Methods: Our analysis included patients from a US nationwide database with LA-NSCLC who received consolidative durvalumab between 2017 and 2023 and had subsequent systemic therapy, classified as PD-L1 monotherapy, PD-L1+chemotherapy, chemotherapy alone, PD-L1+CTLA4, or targeted therapy (TT).
Results of an Integrated Phase I/II Prospective Clinical Trial (NEXIS) for Neoadjuvant Anti-PD-L1 (Durvalumab) and Anti-CTLA-4 (Tremelimumab) With Radiation for High-Risk Soft-Tissue Sarcoma of the Trunk and Extremities.
Cureus
October 2024
Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, USA.
Article Synopsis
- - The study explores the effectiveness and safety of combining checkpoint inhibitor immunotherapy with radiation therapy for high-risk soft tissue sarcomas in a phase I/II trial, focusing on patients with tumors larger than 5 cm.
- - Out of 23 patients enrolled, only 18 completed the full treatment protocol, with significant adverse effects observed in the majority, but 44.4% showed an excellent histological response post-treatment.
- - The trial, known as the NEXIS trial, included treatments with anti-PD-L1 and anti-CTLA-4 therapies followed by surgery and was registered on ClinicalTrials.gov to ensure oversight and transparency.
Immune checkpoint inhibitors for glioblastoma: emerging science, clinical advances, and future directions.
J Neurooncol
November 2024
Department of Neurosurgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.
Glioblastoma (GBM), the most common and aggressive primary central nervous system (CNS) tumor in adults, continues to have a dismal prognosis. Across hundreds of clinical trials, few novel approaches have translated to clinical practice while survival has improved by only a few months over the past three decades. Randomized controlled trials of immune checkpoint inhibitors (ICIs), which have seen impressive success for advanced or metastatic extracranial solid tumors, have so far failed to demonstrate a clinical benefit for patients with GBM.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!